Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis.
Mucoepidermoid carcinoma (MEC) of the lung needs to be carefully distinguished from other lung tumors with similar features, particularly from adenosquamous carcinoma, this latter tumor frequently showing EGFR mutations. In contrast with the data reported by Han et al in the last July issue of Lung Cancer, neither EGFR nor K-RAS mutations were observed in MEC from caucasian patients.
Rossi
Giulio
G
Sartori
Giuliana
G
Cavazza
Alberto
A
Tamberi
Stefano
S
D000368:Aged; D018277:Carcinoma, Mucoepidermoid / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D003937:Diagnosis, Differential; D004848:Epithelium / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics*; D005260:Female; D011905:Genes, ras; D006801:Humans; D007633:Keratins / Q000378:metabolism; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D055271:Mucin 5AC / Q000378:metabolism; D009077:Mucins / Q000378:metabolism; D009154:Mutation
C524678:MUC5AC protein, human; D055271:Mucin 5AC; D009077:Mucins; D007633:Keratins; D066246:ErbB Receptors